Skip to content

Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies

Stephanie L. Borgland, Drew M. Neyens

Journal of Psychiatry and Neuroscience June 1, 2022 DOI: 10.1503/jpn.220090 via OpenAlex

Summary

AI-generated from the abstract

Private clinics and registered clinical trials using serotonergic psychedelics for psychiatric conditions such as substance use disorder and major depressive disorder have grown substantially. Classical psychedelics include lysergic acid diethylamide.

Study at a glance

Characteristics Peer reviewed
Topics Depression LSD Serotonin
Keywords Psychiatry Hallucinogen Medicine
Citations 14
Key finding There has been substantial growth in private clinics and registered clinical trials employing serotonergic psychedelics for psychiatric illnesses including substance use disorder and major depressive disorder.

Abstract

There has been a substantial growth in private clinics and registered clinical trials employing serotonergic psychedelics for various psychiatric illnesses, including substance use disorder[1][1],[2][2] and major depressive disorder.[3][3]–[6][4] Classical psychedelics include lysergic acid

Explore topics

Comments

No comments yet.

Log in to comment